Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026, Highlighting Immunology Pipeline
Tonix Pharmaceuticals will participate in BTIG Infectious Disease Day 2026, showcasing its immunology programs including a Lyme disease prophylaxis candidate, underscoring its expansion beyond CNS treatments.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial-stage biotechnology company, announced that members of its management team will participate in one-on-one meetings at BTIG’s Infectious Disease Day 2026, to be held virtually on June 16, 2026. Seth Lederman, M.D., president and chief executive officer of Tonix Pharmaceuticals, will represent the company during the event. The announcement signals Tonix’s strategic focus on its immunology pipeline, which includes monoclonal antibody candidates for infectious diseases and transplant rejection.
The participation in BTIG’s Infectious Disease Day is significant as it highlights Tonix’s expansion beyond its established central nervous system (CNS) franchise. Tonix is best known for its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports marketed products for acute migraine, including Zembrace® SymTouch® and Tosymra®. However, Tonix is now leveraging its scientific expertise to address high unmet needs in immunology.
Among the immunology programs advancing is TNX-4800, a monoclonal antibody for Lyme disease prophylaxis. Lyme disease, caused by Borrelia burgdorferi, affects hundreds of thousands annually, and a prophylactic option could significantly reduce disease burden. Another key program is TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection, a critical need for transplant recipients. These programs, along with CNS candidates like TNX-2900 for Prader-Willi syndrome, underscore Tonix’s broad pipeline.
The company’s presence at a dedicated infectious disease conference suggests growing investor interest in its immunology assets. Tonix is also maximizing the science behind TONMYA, with Phase 2 trials evaluating its potential in major depressive disorder and acute stress disorder. The recent FDA approval of TONMYA provides a commercial foundation, but the immunology pipeline offers diversification and potential for future growth.
Investors can find the latest news and updates relating to TNXP in the company’s newsroom at https://ibn.fm/TNXP. For the full press release, visit https://ibn.fm/38XUG. Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.